All posts by PIER MARIA FORNASARI

Gene Editing in Patient-derived Heart Cells May Be Useful in FA

Removal of the genetic defect that causes Friedreich’s ataxia (FA) in heart cells derived from a patient with heart disease associated with FA reversed the cells’ abnormal molecular profile, a study shows. This gene-editing strategy could be a useful tool for regenerative medicine aimed at treating heart defects associated with the condition. The study, “Excision of the

Read More


New Articles in The CRISPR Journal

The CRISPR Journal announces the publication of its August 2019 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. The Journal, led by

Read More


New research published in cancer discovery identifies new drug target for glioblastoma

 A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells. While previous research has shown that a protein called

Read More


South Korea to revise bill to enable gene therapy research using gene editing

South Korea is seeking to ease legislative restrictions to allow research on breakthrough gene therapies using gene editing and other advanced gene correction tools. The Ministry of Health and Welfare said on Thursday it is revising the Bioethics Act to allow gene therapy research in this direction.  Rep. Yoon Il-kyu of the ruling Democratic Party,

Read More


Moving Towards Automated Manufacturing for Cell Therapies

As more cell therapy products reach the “finish line” of U.S. Food and Drug Administration (FDA) approval and new regenerative medicine products begin the clinical development process, the need for expanded manufacturing capacity that can support long-term commercial business models is increasing. Recently, David Smith, Alex Klarer, Thomas Heathman, Courtney LeBlon, Yasuhiko Tada and Brian

Read More


FDA and Congress Move to Stop Unproven Stem Cell Interventions

Agency’s jurisdiction over regenerative therapies upheld in landmark court ruling The Food and Drug Administration and members of Congress have taken important steps in recent months to protect consumers from unproven and risky stem cell products offered by hundreds of clinics nationwide. However, the agency needs to take broader action to deter businesses from selling

Read More